Skip to content
Calculator
Evidence: HighPeptideDiscontinuedHIV fusion inhibitorFDA-approved 2003 · now discontinuedInjected twice daily

Enfuvirtide

A synthetic piece of HIV's own gp41 protein that blocks the virus from fusing with cells, the first drug of its kind

A synthetic peptide copied from part of HIV-1's gp41 envelope protein that blocks the virus from fusing with cells; approved in 2003 as Fuzeon, the first HIV fusion inhibitor.

Used in human trials: 90 mg, Twice daily, Subcutaneous (Trial: treatment-experienced HIV (TORO 1 and 2)) Details ↓

Overview

What is it?

To infect a cell, HIV merges its membrane with the cell's, a step driven by gp41, the transmembrane part of its envelope protein. Enfuvirtide binds gp41 and blocks that fusion. It was the first approved fusion inhibitor.

Two phase 3 trials, TORO 1 in the Americas and TORO 2 in Europe and Australia, enrolled people whose HIV resisted the three older drug classes. Added to an optimized regimen, enfuvirtide lowered viral load and raised CD4 counts more than the regimen alone over 24 weeks. Routine use bore that out: in a Mexican cohort of heavily treated adults, two-thirds reached undetectable virus at 24 weeks. A phase II trial before them found the antiviral effect rose with dose up to 90 mg twice daily.

The cost was the injections. Injection-site reactions occurred in nearly everyone, and biopsies show scleroderma-like changes in the skin that outlast treatment by more than a year. TORO patients also gained truncal and abdominal fat. Resistance arises through mutations in gp41, and they persist longer the longer a failing regimen is kept. Changing the delivery did not fix that: a shorter needle and a needle-free injector gave similar induration in the OPTIONS trial, though most patients then chose the injector. People in the TORO trials still reported quality of life that held or improved, and in healthy volunteers a week of injections moved no metabolic, kidney or liver marker.

Its later role shrank. Adding it to first-line treatment in very advanced HIV sped viral suppression but did not improve immune recovery or AIDS events, and short courses added nothing for treatment-experienced patients. As integrase inhibitors arrived, suppressed patients switched from enfuvirtide to raltegravir and stayed suppressed without the injections. The intended successor, tifuvirtide (T-1249), held its activity against virus that had escaped enfuvirtide in two short studies, but its development was discontinued in 2004 and no phase 3 trial was ever run.

Drugs@FDA now lists Fuzeon as discontinued and DailyMed carries no current maker's label, so the dose and half-life here come from the trials and a pharmacokinetics review rather than a label. A once-daily 180 mg schedule matched twice-daily dosing for total exposure but left lower troughs and a trend toward weaker early viral suppression.

90 mg
Twice daily under the skin
TORO trials · PMID 12773645
98%
Had injection-site reactions
TORO pooled, 48 weeks · PMID 16280695
2003
First fusion inhibitor approved
Now discontinued in the US · Drugs@FDA
Science

Mechanism of Action

Enfuvirtide is a synthetic peptide that matches part of HIV's gp41 and binds it, stopping the virus fusing with the cell membrane.

🧬

Blocks gp41 fusion

Binds gp41 and prevents the viral and cell membranes merging.

🛑

Acts outside the cell

Works before the virus enters, so it kept working against strains resistant to drugs that act inside the cell.

⏱️

Short-lived

Bioavailability 84.3% after injection under the skin and a half-life of about 3.8 hours, hence twice-daily dosing.

Evidence

Published Research

The studies behind enfuvirtide, read from their PubMed abstracts.

Human1998

The first human study: T-20 into a vein, 16 adults

Sixteen adults with HIV received intravenous T-20 alone for 14 days at 3 to 100 mg twice daily. Viral load fell with dose; all four on 100 mg twice daily dropped below 500 copies/mL, a median fall of 1.96 log10.

PMID: 9809555
Human2003

TORO 1: the Americas, 501 patients

People in the Americas with HIV resistant to three drug classes were randomized 2:1 to enfuvirtide plus an optimized regimen or the regimen alone. At 24 weeks viral load fell 1.696 log10 against 0.764; CD4 counts rose by 76 against 32 cells/mm³.

PMID: 12637625
Human2003

TORO 2: Europe and Australia, 512 patients

Patients with a median of 12 previous drugs took enfuvirtide 90 mg twice daily plus an optimized regimen, or the regimen alone. At 24 weeks viral load fell 1.429 log10 against 0.648, and CD4 counts rose by 65.5 against 38.0 cells/mm³.

PMID: 12773645
Human2005

Both TORO trials pooled: 48-week safety, 997 patients

Injection-site reactions occurred in 98% of enfuvirtide patients and led 4.4% to stop. Pneumonia (6.7 against 0.6 events per 100 patient-years) and swollen lymph nodes (7.1 against 1.2) were more frequent than on the background regimen alone.

PMID: 16280695
Human2013

Intensifying first treatment in advanced HIV

In 195 previously untreated patients with very low CD4 counts, adding enfuvirtide for 24 weeks suppressed virus faster (74% against 58% below 50 copies at week 24) but did not raise CD4 recovery or reduce AIDS events; by week 48 both arms were at 79%.

PMID: 23165467
Human2012

Very late presenters: a pilot

In 22 patients starting treatment with CD4 counts around 20, adding enfuvirtide gave a larger CD4 rise at week 24 (207 against 134 cells) and more reached 200 cells (70% against 12.5%).

PMID: 22135137
Human2012

Short intensification: no benefit

In 29 treatment-experienced patients, three months of added enfuvirtide did not improve virological response at week 24 (79% against 93% below 50 copies) or HIV DNA levels.

PMID: 22997073
Human2011

Switching to raltegravir

In suppressed patients with multidrug-resistant HIV, switching from enfuvirtide to raltegravir kept 90% below 50 copies at week 48, ending the injections.

PMID: 21712241
Human2011

Body fat in TORO

Over 48 weeks, glucose and lipids were unchanged, but the enfuvirtide group gained about 1 kg and showed increases in truncal and abdominal fat not seen in controls.

PMID: 20497250
Human2011

What the injection sites show

Biopsies of injection-site reactions showed scleroderma-like collagen changes that persisted more than a year after enfuvirtide was stopped.

PMID: 21332688
Human2014

Routine use in Mexico

In 40 highly treatment-experienced adults, 65.8% were below 50 copies at 24 weeks and 55.5% at 48 weeks, CD4 counts rose, and every patient reported injection-site pain.

PMID: 25553058
Human2011

Resistance after failure

In patients failing enfuvirtide, gp41 mutations such as V38A and N43D were found and archived in viral DNA in 5 of 7, with persistence linked to how long the failing drug was continued.

PMID: 21341978
Human2010

Children and adolescents

In 11 treatment-experienced children and adolescents in a Spanish cohort, enfuvirtide combined with newer drugs led to undetectable virus and immune recovery; without them, virus was not fully suppressed.

PMID: 20334565
Human2003

Phase II: three doses

In a 48-week open-label phase II trial in 71 protease-inhibitor-experienced adults, enfuvirtide at 45, 67.5 or 90 mg twice daily added to a four-drug background regimen gave a larger viral-load fall than the background alone (-2.24 against -1.87 log10 copies/ml) and more patients below 400 copies (54.9% against 36.8%), with injection-site reactions in 68.5% and no dose-related adverse events.

PMID: 14518696
Human2008

OPTIONS: needles against a needle-free injector

In the OPTIONS trial, 60 people already on enfuvirtide were randomised to a 27-gauge needle, a shorter 31-gauge needle or a gas-powered needle-free injector; injection-site induration was similar across the three at 12 weeks (38%, 25% and 42% below grade 2), viral load was unaffected, and 85% chose the needle-free device afterwards.

PMID: 18572758
Human2004

Quality of life in the TORO trials

Pooling 995 treatment-experienced people from TORO 1 and 2, self-injected enfuvirtide (90 mg twice daily) with an optimised regimen did not worsen any quality-of-life measure over 24 weeks, improved general health at every visit, and gave a higher mental health summary score at 24 weeks than the regimen alone.

PMID: 15319673
Human2006

Once a day against twice

In a randomised crossover study in 37 people with HIV, 180 mg once daily gave the same total exposure as 90 mg twice daily (AUC ratio 0.98) but a 49% higher peak and a 57% lower trough, and a trend toward a smaller viral-load fall at day 7 (1.0 against 1.4 log10, p = 0.07) that tracked the trough.

PMID: 16439873
Human2019

Healthy volunteers: no toxicity signal

In a randomised placebo-controlled crossover trial in healthy adults (12 given enfuvirtide 90 mg twice daily for 7 days), there were no significant changes in lipids, glucose, mitochondrial DNA, kidney or liver markers, and no symptoms of toxicity.

PMID: 31120908
Review2005

How the body handles it

At 90 mg twice daily under the skin, absorption is slow and almost complete (bioavailability 84.3%), the half-life is 3.8 hours and 92% is bound to plasma proteins. It showed little potential to interact with drugs processed by the main liver enzymes.

PMID: 15656696
Review2012

The injection-site reactions in detail

Injection-site reactions occur in nearly everyone treated, from little or nothing to cysts, nodules and scleroderma-like hardening; most are self-limited.

PMID: 23134996
Dosing

Dosing Data

In the TORO trials enfuvirtide was injected under the skin at 90 mg twice daily with an optimized regimen; the US product is now discontinued.

Discontinued in the US; doses below come from the trials. Injection-site reactions occur in nearly everyone.
ProtocolDoseFrequencyDurationRoute
Trial: treatment-experienced HIV (TORO 1 and 2) Human studyPMID 1263762590 mgTwice daily24 to 48 weeksSubcutaneous

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

Discontinued
Enfuvirtide was a fixed 90 mg twice-daily injection; the US product is no longer marketed.
Open Calculator →
For Buyers

What a Buyer Needs to Know

What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.

What is sold

Unknown: we hold no label and no published test that says what forms or vial sizes Enfuvirtide is sold in. A vial's own label is a seller's claim, not a source.

Mixing a vial: a worked example

An arithmetic example, not a recommendation: a 10 mg vial mixed with 3 mL of bacteriostatic water holds 3,333.3 mcg per mL, so 90 mg, the “Trial: treatment-experienced HIV (TORO 1 and 2)” row would be 2700.0 units, more than a 1 mL U-100 syringe holds. Put your own vial's numbers into the reconstitution calculator.

Source: dose: Used in human trials, PMID 12637625 (Dosing Data below); vial and water: the calculator's default example, not a vial size we have a source for.

Storage before and after mixing

Unknown: no label or published stability study on file says how to store Enfuvirtide, before or after mixing. The mixing guide sets out the general rules, with their sources: keep a mixed vial in the fridge, and use it promptly, as the bacteriostatic water label says of any drug dissolved in it. The 28 days often quoted is the limit for an opened multiple-dose vial from a manufacturer, an outer limit set for sterility, not a time a mixed solution has been shown to keep. Nobody has published how long Enfuvirtide stays intact once mixed.

How it is taken

As it was given in human studies: Subcutaneous (Twice daily; Trial: treatment-experienced HIV (TORO 1 and 2)).

For injection technique, sites and needle disposal, see the mixing guide.

Source: Used in human trials: the route and frequency of each row in Dosing Data below.

What to expect, and when

How long it stays in the body: a half-life of about 3.8 hours after subcutaneous injection. After about five half-lives almost none is left.

How long the doses were given: Trial: treatment-experienced HIV (TORO 1 and 2): 24 to 48 weeks.

When effects appear: unknown; no source on this page gives a time to effect for Enfuvirtide. Results reported in the studies are under Published Research.

Source: half-life: PMID 15656696; Used in human trials, the duration of each row in Dosing Data below.

Side effects, and when to stop or get help

From the Side Effects section: Injection-site reactions in 98% of patients, which led 4.4% to stop over 48 weeks (pooled TORO data); Pneumonia more often than on the background regimen alone: 6.7 against 0.6 events per 100 patient-years; Swollen lymph nodes: 7.1 against 1.2 events per 100 patient-years. Full list and cautions ↓

When to stop or get help: unknown; no label or trial on file sets rules for stopping Enfuvirtide. Treat a severe or unexpected reaction as a reason to stop and see a doctor.

Source: the Side Effects section below (“From the studies above”).

Interactions

  • ritonavir and ritonavir-boosted saquinavir: no pharmacokinetic interaction in HIV-1-infected patients
  • rifampicin: no enzyme-inducing effect on enfuvirtide pharmacokinetics

Every peptide's record, with its source: the interaction matrix.

Source: human study, PMID 15199084; human study, PMID 14615475.

Checking what you bought

Unknown: no published independent test of Enfuvirtide products is in our lab-results database yet, so how products sold under this name measure up is not known.

To read a certificate of analysis, paste it into the COA decoder; it checks the measured mass against Enfuvirtide's expected mass, 4,492.0 Da, from this entry's molecular data. Trust & Verification explains what independent testing can and cannot show.

Legal status

US: Discontinued (Fuzeon (enfuvirtide), NDA 021481, was first approved in the US on March 13, 2003). Sport: Not on the 2026 List.

Country by country ↓ · Regulatory tracker

Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.

Safety

Side Effects & Contraindications

Reported Side Effects

From the studies above.

● Injection-site reactions in 98% of patients, which led 4.4% to stop over 48 weeks (pooled TORO data)
● Pneumonia more often than on the background regimen alone: 6.7 against 0.6 events per 100 patient-years
● Swollen lymph nodes: 7.1 against 1.2 events per 100 patient-years

Contraindications & Cautions

There is no current US label to quote; from the EU product information summary (EMA).

● Allergy to enfuvirtide or any other ingredient of the product
● Tested athletes — see the Sport (WADA) row below
Questions

Frequently Asked Questions

?What is enfuvirtide?

A synthetic peptide copied from part of HIV-1's gp41 envelope protein. It blocks the virus from fusing with the cells it infects and was sold as Fuzeon, the first HIV fusion inhibitor.

?Is Fuzeon still available?

Drugs@FDA lists Fuzeon as discontinued in the US, and DailyMed carries no current maker's label. Its EU status today was not verified here.

?How was it taken?

In the phase 3 TORO trials, 90 mg was injected under the skin twice a day alongside other HIV drugs.

Bibliography

References

  1. [fda] US FDA, Drugs@FDA (openFDA): FUZEON (enfuvirtide), NDA 021481, original approval March 13, 2003, marketing status Discontinued. Read October 2, 2026.
  2. [other] European Medicines Agency. Fuzeon (enfuvirtide) EPAR: marketing authorisation granted May 27, 2003, renewed May 27, 2008. Read October 2, 2026.
  3. [clinical-trial] Kilby JM, et al. "Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry." Nat Med, 1998;4(11):1302-7. PMID: 9809555.
  4. [clinical-trial] Lalezari JP, et al. "Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America." N Engl J Med, 2003;348(22):2175-85. PMID: 12637625.
  5. [clinical-trial] Lazzarin A, et al. "Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia." N Engl J Med, 2003;348(22):2186-95. PMID: 12773645.
  6. [clinical-trial] Trottier B, et al. "Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks." J Acquir Immune Defic Syndr, 2005;40(4):413-21. PMID: 16280695.
  7. [pubmed] Patel IH, et al. "Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide." Clin Pharmacokinet, 2005;44(2):175-86. PMID: 15656696.
  8. [pubmed] Mirza RA, et al. "Enfuvirtide and cutaneous injection-site reactions." J Drugs Dermatol, 2012;11(10):e35-8. PMID: 23134996.
  9. [pubmed] Joly V, et al. "Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo)." Antimicrob Agents Chemother, 2013;57(2):758-65. PMID: 23165467.
  10. [pubmed] Bonora S, et al. "Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study." Infection, 2012;40(1):69-75. PMID: 22135137.
  11. [pubmed] Morand-Joubert L, et al. "Lack of benefit of 3-month intensification with enfuvirtide plus optimized background regimen (OBR) versus OBR alone in patients with multiple therapeutic failures: the INNOVE study." J Med Virol, 2012;84(11):1710-8. PMID: 22997073.
  12. [pubmed] Gallien S, et al. "Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial." J Antimicrob Chemother, 2011;66(9):2099-106. PMID: 21712241.
  13. [pubmed] Cooper DA, et al. "The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy." HIV Med, 2011;12(1):31-9. PMID: 20497250.
  14. [pubmed] Wallace BJ, et al. "Enfuvirtide injection site reactions: a clinical and histopathological appraisal." Australas J Dermatol, 2011;52(1):19-26. PMID: 21332688.
  15. [pubmed] Huerta-García G, et al. "Effectiveness of enfuvirtide in a cohort of highly antiretroviral-experienced HIV-1-infected patients in Mexico." AIDS Res Ther, 2014;11(1):323. PMID: 25553058.
  16. [pubmed] Charpentier C, et al. "Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy." Scand J Infect Dis, 2011;43(5):373-9. PMID: 21341978.
  17. [pubmed] Palladino C, et al. "Short communication: evaluation of the effect of enfuvirtide in 11 HIV-1 vertically infected pediatric patients outside clinical trials." AIDS Res Hum Retroviruses, 2010;26(3):301-5. PMID: 20334565.
  18. [pubmed] Lalezari JP, et al. "A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults." Antivir Ther, 2003;8(4):279-87. PMID: 14518696.
  19. [pubmed] Boyd MA, et al. "A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study)." Antivir Ther, 2008;13(3):449-53. PMID: 18572758.
  20. [pubmed] Cohen CJ, et al. "Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen." J Acquir Immune Defic Syndr, 2004;37(1):1140-6. PMID: 15319673.
  21. [pubmed] Thompson M, et al. "Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects." AIDS, 2006;20(3):397-404. PMID: 16439873.
  22. [pubmed] Barroso S, et al. "Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers." PLoS One, 2019;14(5):e0216712. PMID: 31120908.

Sources & Citations

Studies were read from their PubMed abstracts; there is no current label. Read October 6, 2026.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.

Last reviewed: 2026-11-04